In a genome-wide screen using differential methylation hybridization (DMH), we have identified a CpG island within the 5 0 region and untranslated first exon of the secretory granule neuroendocrine protein 1 gene (SGNE1/ 7B2) that showed hypermethylation in medulloblastomas compared to fetal cerebellum. Bisulfite sequencing and combined bisulfite restriction assay were performed to confirm the methylation status of this CpG island in primary medulloblastomas and medulloblastoma cell lines. Hypermethylation was detected in 16/23 (70%) biopsies and 7/8 (87%) medulloblastoma cell lines, but not in nonneoplastic fetal (n ¼ 8) cerebellum. Expression of SGNE1 was investigated by semi-quantitative competitive reverse transcription-polymerase chain reaction and found to be significantly downregulated or absent in all, but one primary medulloblastomas and all cell lines compared to fetal cerebellum. After treatment of medulloblastoma cell lines with 5-aza-2 0 -deoxycytidine, transcription of SGNE1 was restored. No mutation was found in the coding region of SGNE1 by single-strand conformation polymorphism analysis. Reintroduction of SGNE1 into the medulloblastoma cell line D283Med led to a significant growth suppression and reduced colony formation. In summary, we have identified SGNE1 as a novel epigenetically silenced gene in medulloblastomas. Its frequent inactivation, as well as its inhibitory effect on tumor cell proliferation and focus formation strongly argues for a significant role in medulloblastoma development.
In a genome-wide screen using differential methylation hybridization (DMH), we have identified a CpG island within the 5 0 region and untranslated first exon of the secretory granule neuroendocrine protein 1 gene (SGNE1/ 7B2) that showed hypermethylation in medulloblastomas compared to fetal cerebellum. Bisulfite sequencing and combined bisulfite restriction assay were performed to confirm the methylation status of this CpG island in primary medulloblastomas and medulloblastoma cell lines. Hypermethylation was detected in 16/23 (70%) biopsies and 7/8 (87%) medulloblastoma cell lines, but not in nonneoplastic fetal (n ¼ 8) cerebellum. Expression of SGNE1 was investigated by semi-quantitative competitive reverse transcription-polymerase chain reaction and found to be significantly downregulated or absent in all, but one primary medulloblastomas and all cell lines compared to fetal cerebellum. After treatment of medulloblastoma cell lines with 5-aza-2 0 -deoxycytidine, transcription of SGNE1 was restored. No mutation was found in the coding region of SGNE1 by single-strand conformation polymorphism analysis. Reintroduction of SGNE1 into the medulloblastoma cell line D283Med led to a significant growth suppression and reduced colony formation. In summary, we have identified SGNE1 as a novel epigenetically silenced gene in medulloblastomas. Its frequent inactivation, as well as its inhibitory effect on tumor cell proliferation and focus formation strongly argues for a significant role in medulloblastoma development.
Introduction
Medulloblastomas are malignant primitive neuroectodermal tumors arising in the cerebellum. They represent the most common non-glial malignancy of the brain in children and comprise up to 25% of all intracranial neoplasms in the pediatric age group (Kleihues et al., 2002) . Advances in modern surgery and the introduction of optimized regimens of adjuvant radiotherapy and chemotherapy have improved the outcome for children from 10 to 50-70% in the past 30 years (Russo et al., 1999) . To improve further the outcome of medulloblastoma patients, novel insights into the biology of these tumors is required. Numerous studies have described genetic rearrangements, for example, losses, gains and mutations of various chromosomal regions in medulloblastomas. Losses on chromosome 17p through i(17q) (Biegel et al., 1989) or unbalanced translocation and loss of heterozygosity (LOH) on chromosome 1q, 8p, 10q, 11, 16q and 17p was frequently found Kraus et al., 1996; Reardon et al., 1997) . For many of these regions the target is still unknown. DNA methylation is generally viewed as an alternative pathogenetic mechanism, but investigations of epigenetic alterations in medulloblastomas are still scarce.
Recent studies have shown that the tumor suppressor genes RASSF1, Caspase 8 and HIC-1 are transcriptionally silenced by epigenetic alterations in medulloblastomas (Fru¨hwald et al., 2001; Waha et al., 2003; Lindsey et al., 2005) . Methylation of the INK4C (CDKN2C) promoter and loss of p18 (INK4c) protein was detected in a significant fraction of medulloblastomas (Uziel et al., 2006) . To investigate the prevalence and role of aberrant promoter methylation in medulloblastoma on a genome-wide scale and to identify new genes epigenetically altered in this tumor entity, we have used a microarray-based differential methylation hybridization (DMH) analysis. The DMH procedure was performed as described (Yan et al., 2001; Waha et al., 2005) . We have identified a CpG island (definition according to Gardiner-Garden and Frommer, 1987) that showed hypermethylation in 5 out of 10 medulloblastomas, but not in normal fetal cerebellum that was located 1.6 kb upstream of the initiator ATG within the 5 0 -UTR and first untranslated exon of the secretory granule neuroendocrine protein 1 gene (SGNE1; Figure 1a ; modified from Mbikay et al., 2001 and Strausberg et al., 2002) , the human homologue of the murine neuroendocrine gene 7B2. 7B2 binds to (Braks and Martens, 1994; Zhu and Lindberg, 1995) and functions as a specific chaperone for proprotein convertase-2 (PC2) and facilitates its movement toward the secretory pathway, where the zymogen is proteolytically matured and activated (Zhu and Lindberg, 1995) . 7B2 is a member of a group of Ca 2 þ -dependent serine proteases that show homology to the endoproteases, subtilisin (bacteria) and kexin (yeast). It maps to chromosome 15q11-15 (Mattei et al., 1990) , a region which is altered in patients with Prader-Willi syndrome (Cassidy, 1997) . 7B2, was first isolated from porcine and human pituitary glands and is selectively expressed in the central nervous system and endocrine tissues (Hsi et al., 1982; Seidah et al., 1983; Iguchi et al., 1984) . Studies of Seidel et al. (1998) demonstrated that the distribution of 7B2 was pan-neuronal in rat brain and expressed in ependymal cells and the subcommissural organ. Jeannotte et al. (1997) indicate that PC2 and 7B2 are coinduced and processed during neuronal differentiation of P19 cells. Since 7B2 has been implicated in cancer and altered expression was found in various types of human tumors (reviewed in Mbikay et al. (2001) ), our observations led us to further investigate this gene in medulloblastomas. 0 -UTR region and first untranslated exon. Location and relative distances of the CpG sites 1-18 investigated by bisulfite sequencing are indicated. CpG island search was performed using the 'Meth primer' software. CGI: CpG island. (b) Reverse bisulfite sequencing profile of a medulloblastoma (D1573) and fetal cerebellum (D1583). Methylated CpG and unmethylated CpA sites 8-13 are underlined and in bold. Genomic DNA of primary tumors, cell lines and non-neoplastic fetal cerebellar tissue was extracted and treated with sodium bisulfite as described (Waha et al., 2005) . Primers used for PCR amplification were SGNE1 fw-5 0 -atttgggatgtagtttggggagttt-3 0 and SGNE1 rev-5 0 -aatactcccttccccttactaataa-3 0 . The 341-bp PCR product contains 18 putative CpG methylation sites. Bisulfite PCR products were cloned into the TOPO TA cloning/pCR2.1 vector (Invitrogen, Karlsruhe, Germany). Inserts of individual bacterial clones were amplified, purified with the high pure PCR purification kit (Roche, Mannheim, Germany) and sequenced using the BigDye Prism DNA sequencing kit (Applied Biosystems, Foster City, CA, USA). Single clone sequences were analysed and diagrams were generated with the BiQ Analyzer software (Bock et al., 2005) . (c) Summary of bisulfite sequencing analysis of CpG sites 1-18 of individual clones in medulloblastomas, cell lines and normal fetal cerebellum. () Methylated CpG site; (J) unmethylated CpG site; a single-nucleotide polymorphism affecting one of the contained CpG sites is indicated by a small vertical lines without a circle; no circle and no vertical line: no valid sequence information available. (d) COBRA analysis of the first untranslated exon and first intron of SGNE1. The 341-bp PCR products generated with SGNE1 primers from bisulfite-treated tumor and control DNA were digested with the restriction enzyme TaqaI (NEB), yielding fragments of 216 and 125 bp and subsequently separated on 10% acrylamide gels. Restriction fragments are only apparent in medulloblastomas and not in normal fetal cerebellum (FC). Tumor 635 is a myxopapillary ependymoma (EI) and 1088 an AT/RT (atypical teratoid/rhabdoid tumor).
SGNE1/7B2 is hypermethylated and inactivated in medulloblastomas A Waha et al
Aberrant methylation within the 5 0 -UTR and first exon of SGNE1 To validate the microarray data, bisulfite sequencing and combined bisulfite restriction assay (COBRA) analysis of 23 medulloblastomas and eight cell lines as well as eight fetal cerebellar samples was conducted. Figure 1b shows representative sequencing profiles of CpG sites 8-13 within the region analysed in medulloblastoma samples and fetal cerebellum (BC005349 range ¼ chr.15:30649863-30650204). The tumor sample exhibits complete methylation of all CpG sites, whereas fetal cerebellum shows a complete lack of methylation in this region. The comparison from individual clones of 10 primary tumor samples and four cell lines with eight normal fetal cerebellar tissues clearly showed significant accumulation of de novo methylation in the selected tumor samples and cell lines (Figure 1c ). The overall percent methylation was 85% in primary tumor samples, 95% in cell lines and only 3% in fetal cerebellum samples; which were, therefore, scored as not-methylated. Tumor sample 810 showed a heterogeneous methylation pattern. The TaqaI restriction site flanked by the primer sequences was found to be frequently hypermethylated in the tumor samples in comparison to fetal cerebellum and was used to scan the methylation status of SGNE1 in an expanded set of tumor samples by COBRA (Figure 1d ). Polymerase chain reaction (PCR) products of tumor samples were frequently cut by TaqaI (indicating presence of methylated alleles), whereas no restriction fragments were seen after digestion of fetal brain tissues (FC) as well as in MB, for example, D538, D1633 and D1066, confirming trace or absent methylation in these cases. COBRA analysis revealed a good concordance with the bisulfite sequencing data. De novo methylation of SGNE1 was found in 16 out of 23 (70%) of the primary medulloblastomas and in 7 out of 8 (87%) of the cell lines but in none of the 8 fetal cerebellar samples. It is interesting to note that methylation was more frequent in classic medulloblastoma (12/15; 80%) than in desmoplastic tumors (4/8; 50%). The data clearly demonstrate that methylation of the CpG island upstream of the SGNE1 transcription start site is a frequent and tumorspecific epigenetic event in medulloblastomas.
SGNE1 expression is significantly reduced in medulloblastomas and can be reactivated in medulloblastoma cell lines treated with 5-aza-2 0 -deoxycytidine To investigate if CpG island methylation directly affects the expression of SGNE1, we used a competitive reverse transcription (RT)-PCR approach with specific RNA competitor molecules for SGNE1 and the housekeeping gene b2-microglobulin. Expression levels of SGNE1 were analysed in 14 classic and 12 desmoplastic medulloblastomas, eight cell lines and six normal fetal cerebellar tissues for which RNA was available Figure 2 Relative transcript levels of SGNE1 (SGNE1/b2-microglobulin) analysed by semiquantitative competitive (cRT-PCR). Inset: comparative data for SGNE1 transcription in classic and desmoplastic medulloblastomas, cell lines and fetal cerebella. Competitor molecules with internal deletions for SGNE1 and the housekeeping gene b2-microglobulin were generated by in vitro mutagenesis as described (Waha et al., 1998) . The following primers were used: SGNE1 fw 5 0 -ggactttagtgaggatcagg-3 0 (exon 2) and SGNE1 rev 5 0 -(6-FAM)agcctggatagtcatgttcc-3 0 (exon 3), yielding products of 164 bp for the endogenous transcript and 147 bp for the competitor molecule; b2-microglobulin fw 5 0 -tgtctttcagcaaggactgg-3 0 and b2-microglobulin rev 5 0 -(6-FAM)gatgctgcttacatgtctcg-3 0 , endogenous product size 148 bp, competitor 128 bp. PCR products were separated on 4.5% denaturating acrylamide gels. Expression levels were calculated using the following algorithm:
ðSGNE1 endogenous =SGNE1 competitor Þ=ðb2 À microglobulin endogenous =b2 À microglobulin competitor Þ:
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A Waha et al ( Figure 2 ). All but one (D292) of the medulloblastoma tumor samples and all of the cell lines exhibited no or low expression of SGNE1 compared with the fetal cerebellar samples. The mean expression level of all classic medulloblastomas (n ¼ 14) was 0.13, of the desmoplastic tumors (n ¼ 12) 0.69 and of medulloblastoma cell lines (n ¼ 8) 0.18. In contrast, fetal cerebellar samples (n ¼ 6) exhibited a significantly higher transcription, with a mean of 7.12.
Comparison of the expression levels shows that transcription of SGNE1 is reduced in classic medulloblastomas by a factor of 55 when compared with fetal cerebellum (Mann-Whitney test, P ¼ 0.0006). The SGNE1 transcript levels in desmoplastic medulloblastomas is reduced by a factor of 10 compared with fetal cerebellum (Mann-Whitney test, P ¼ 0.001). It is interesting to note that desmoplastic medulloblastomas had higher levels of SGNE1 transcripts than classic medulloblastomas (Mann-Whitney test, P ¼ 0.011) (Figure 2 ). These findings confirm the results of Pomeroy et al. (2002) , who showed in an expression profiling of classic and desmoplastic medulloblastomas using DNA expression microarrays that SGNE1 was one of the candidate genes with higher expression in desmoplastic medulloblastomas compared with classic medulloblastomas. Expression of SGNE1 was also detected on protein levels in normal cerebellum and the desmoplastic medulloblastoma D810, which contains significant levels of transcripts as determined by cRT-PCR. In contrast, classic medulloblastoma, for example, D1103 revealed reduced SGNE1 protein levels (see Supplementary information). 7B2 was analysed by immunohistochemical studies in several different tumor entities. It was present in a small fraction of medullary carcinomas of the thyroid and of pituitary tumors, in gonadotropinomas and corticotromas (reviewed in Mbikay et al., 2001) . Expression analysis of 7B2 in small-cell lung carcinoma (SCLC) of the classic and variant type and in non-SCLC primary tumors and cell lines revealed that 7B2 is a useful marker to discriminate between the two types and that its expression is important for human lung cancer diagnosis (Roebroek et al., 1989) . In paediatric peripheral primitive neuroectodermal tumors (pPNETs) of the bone, another pediatric peripheral neuroectodermal tumor, SGNE1 protein could be detected in 40% of cases, with 3% revealing a strong expression (Collini et al., 1998) . Treatment of Daoy, D425Med and D283Med with 1 mM 5-aza-2 0 -deoxycytidine resulted in a significant increase in SGNE1 transcription (Figure 3a) . The bisulfite sequencing results shown in Figure 3b indicate that 5-aza-2 0 -deoxycytidine treatment of medulloblastoma cell lines led to demethylation of the investigated region. The data suggest that aberrant CpG island methylation contributes to SGNE1 inactivation in human medulloblastomas. Correlation of methylation and expression data demonstrated that, although 70% of the hypermethylated medulloblastomas and 86% of the hypermethylated cell lines showed reduced expression levels of SGNE1, 30% of the analysed primary tumors and 14% of the cell lines exhibited reduced SGNE1 transcription in the absence of methylation in the analysed region. It is possible that, in these latter cases, transcriptional activation of SGNE1 may also be influenced by accessibility of SGNE1 regulatory regions or availability of specific transcription factors (e.g. Pit-1, CRE, AP-1), for which consensus sequences are known to exist in the SGNE1 5 0 region (Waldbieser et al., 1991; Braks et al., 1996) .
Mutation analysis of SGNE1 in medulloblastomas
As we have found seven medulloblastoma biopsies and one medulloblastoma cell line that show no altered methylation pattern after bisulfite sequencing but low expression of the SGNE1 gene, we have screened the coding region of SGNE1 (Acc. No. NM_003020) for mutations to investigate whether structural aberrations 0 -aza-2 0 -deoxycytidine (Sigma, St Louis, MO, USA) for 5 days. Medulloblastoma cell lines were cultured as described (Bigner et al., 1990; Pietsch et al., 1994; Waha et al., 2003) . (b) Bisulfite sequencing of 5-aza-2 0 -deoxycytidine treated ( þ ) or untreated (À) medulloblastoma cell lines. () Methylated CpG site; (J) unmethylated CpG site; a single-nucleotide polymorphism affecting one of the contained CpG sites is indicated by a small vertical lines without a circle; no circle and no vertical line: no valid sequence information available. SGNE1/7B2 is hypermethylated and inactivated in medulloblastomas A Waha et al may also lead to reduced transcription levels. A panel of 33 medulloblastoma biopsies and eight cell lines, including the seven medulloblastoma biopsies and cell line discussed above, was screened for sequence alterations using single-strand conformation polymorphism (SSCP) analysis (see Supplementary information). No mutations were found within the region analysed (data not shown). Sequencing analysis of the 7B2 gene was performed in two different mouse strains (C57BL/6J and C3H/HeJ) showing differential expression of 7B2 in the endocrine pancreas (Schmidt et al., 2006) . 7B2 gene polymorphisms were detected, but these polymorphisms did not cause differential expression of 7B2 in transfected cells. No other mutations in 7B2/SGNE1 have been reported to date.
Reintroduction of SGNE1 inhibits medulloblastoma proliferation and colony formation
To test the influence of SGNE1 expression on crucial tumor biological properties such as cell proliferation or focus formation, SGNE1 was overexpressed in the medulloblastoma cell line D283Med. D283Med cells were transfected with SGNE1 or empty vector and selected with zeocin. SGNE1 expression was monitored by RT-PCR (Figure 4a ). Transfected cells expressing SGNE1 were cultured for 24 and 48 h under serum-free conditions and were pulse-treated with 3 H-thymidine. Re-expression of SGNE1 led to a 66% reduction in cell growth after 24 h (Mann-Whitney test, P ¼ 0.002) and to an 80% growth suppression after 48 h (Mann-Whitney test, P ¼ 0.002; Figure 4b ).
In-colony formation assays, an average of 30 colonies formed when D283Med cells were transfected with SGNE1, compared with an average of 130 colonies formed in the control empty vector-transfected cells (Figure 4c ): expression of SGNE1 caused a 77% decrease in colony number. Thus, both assays indicate a growth inhibitory effect of SGNE1 in the medulloblastoma cell line D283Med. A similar effect was observed by Kobayashi et al. (2003) , who described that inhibition of pituitary cell proliferation is associated with increased expression of 7B2 mRNA, suggesting that 7B2 has growth suppressing abilities in these cell lines. The phenotype of the 7B2 knockout mice generated by Westphal et al. (1999) points to other cellular roles for 7B2. These animals had no demonstrable PC2 activity, were deficient in processing islet hormones and displayed hypoglycemia, hyperproinsulinemia and hypoglucagonemia. However, unlike PC2-null mutants, which are viable, 7B2-null mutants died of severe Cushing syndrome before 9 weeks of postnatal life (Westphal et al., 1999) .
The glioblastoma cell lines U87MG and U118MG show elevated expression of furin, another member of the Ca 2 þ -dependent serine endoprotease family. Transfection of these cell lines with a furin inhibitor, alpha (1)-antitrypsin Portland (PDX), led to a significant reduction in cell proliferation, tumorigenicity and invasiveness, indicating that members of this protein family and the pathways controlling their activity may be involved in tumorigenesis of brain tumors (Mercapide et al., 2002) .
In conclusion, our findings indicate a role for CpG island hypermethylation and transcriptional silencing of SGNE1 in human medulloblastomas. SGNE1 exhibits growth suppressive abilities and is, therefore, an Figure 4 (a) RT-PCR of D283Med cells transfected with SGNE1-pcDNA4.1Myc/his plasmid or pcDNA4.1Myc/his empty vector (c). b2-microglobulin was included as an internal control. SGNE1 RT-PCR product (Acc. No. NM_003020) was digested with HindIII (NEB) and EcoRI (NEB), gel-purified (Qiagen, Hilden, Germany) and ligated into pcDNA4.1Myc/his (Invitrogen), using standard methods. The following primers were used: fw 5 0 -ccaagcttgacaatggtctccaggatg-3 0 , rev 5 0 -gggaattccctctggatccttatcctcatc-3 0 . The SGNE1-pcDNA4.1Myc/his expression vector was transfected into D283Med cells by nucleofection as described (Hartmann et al., 2006) . After 12 h, transfected cells were selected with 400 mg/ml zeocin (Invitrogen). After 2 weeks, zeocin-resistant colonies were picked and screened for SGNE1 expression by RT-PCR. (b) Reintroduction of SGNE1 in D283Med cells led to reduced cellular proliferation. Results of 3 H-thymidine uptake assays after 24 and 48 h. Cells (3 Â 10 4 ) were transfected with SGNE1-pcDNA4.1Myc/his plasmid (') or pcDNA4.1Myc/his empty vector (&) in serum-free medium. Assays were performed at least in quadruplicates. Six hours before completion of the experiment, cells were pulse-treated with 3 H-thymidine (3 mCi/ml, Amersham, Munich, Germany). 3 H-thymidine uptake was determined as previously described (Hartmann et al., 2006) and normalized to the basal uptake in the control cells transfected with empty vector. (c) Representative image of a colony formation assay. Cells (1 Â 10 4 ) were transfected with either SGNE1-pcDNA4.1Myc/his plasmid (SGNE1) or pcDNA4.1Myc/his empty vector (control) (Fugene, Roche). Forty-eight hours after transfection, cells were exposed to 400 mg/ml zeocin (Invitrogen) for a total of 12 days. Assays were carried out in duplicates. Cells were fixed and stained in 20% methanol and crystal violet and colonies with >50 cells were counted.
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